© Reuters. FILE PHOTO: This illustration photo dated March 14, 2021 shows vials labeled “Astra Zeneca COVID-19 Coronavirus Vaccine” and a syringe in front of an AstraZeneca logo displayed. REUTERS / Dado Ruvic / File Photo
(Reuters) – Australian biotech company CSL said Thursday it had committed to its agreement to produce approximately 50 million doses of AstraZeneca (NASDAQ 🙂 ‘s COVID-19 vaccine by 2022.
The announcement came after a media report said that UK drug maker Vaxzevria’s vaccine is no longer made in Australia due to vaccine demand Pfizer (NYSE 🙂 and Modern (NASDAQ :). [nL4N2R91XR]
Pfizer and Moderna have established market dominance by using mRNA-based COVID-19 vaccine technology to fight the pandemic.
CSL added in a brief statement that more than 20 million of the cans have already been produced and the remaining production is expected to complete early next year.
Sydney cafes, gyms and restaurants welcomed fully vaccinated customers earlier this week after a nearly four-month lockdown as Australia aims to live with the coronavirus and gradually reopen with high vaccination rates.
Fusion media or anyone involved in Fusion Media assumes no liability for any loss or damage arising out of reliance on the information contained on this website, including data, prices, charts, and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.